字号·· | 护眼
卫报

CDC以“其他优先事项”为由拒绝批准大批量麻疹检测CDC denies approval for high-volume measles test, citing ‘other priorities’

点「原文对照」整页切到原文,或双击某段只看那段的原文。

2025年2月27日,在得克萨斯州拉伯克市一家提供麻疹、腮腺炎和风疹(MMR)疫苗接种的医疗中心,一名行人走过一块标牌。摄影:罗纳尔多·谢米特/法新社/盖蒂图片社A person walks past a sign at a health center where the measles, mumps and rubella (MMR) vaccine is administered in Lubbock, Texas, on 27 February 2025. Photograph: Ronaldo Schemidt/AFP/Getty Images

加利福尼亚州、俄勒冈州、华盛顿州和夏威夷州的卫生官员要求美国疾病控制与预防中心(CDC)“优先考虑新兴技术”,重新考虑相关决定。

据西海岸卫生联盟致CDC主任埃里卡·施瓦茨的一封信显示,加利福尼亚州和华盛顿州曾于5月请求CDC验证一种新的麻疹检测方法,但在等待两个月后,CDC以“其他竞争性优先事项”为由拒绝了该请求。

California, Oregon, Washington and Hawaii health officials ask CDC ‘prioritizing emerging technologies’ to reconsider California and Washington asked the US Centers for Disease Control and Prevention (CDC) in May to validate a new way to test for measles – but after waiting two months, the CDC denied the request, citing “other competing priorities”, according to a letter from the West Coast Health Alliance to the CDC director, Erica Schwartz.

这封由加利福尼亚州、夏威夷州、俄勒冈州和华盛顿州卫生官员联署的信件,请求施瓦茨重新考虑并验证一种快速、大批量的麻疹检测方法,以应对可能发生的大规模疫情。该联盟还要求CDC制定检测其他高优先级病原体的方案,以备未来疫情之需。

The letter, signed by health officials in California, Hawaii, Oregon and Washington, asks Schwartz to reconsider and validate a rapid, high-volume measles test in preparation for major outbreaks. The alliance also asked the CDC to create protocols to test for other high-priority pathogens to prepare for future outbreaks.

阅读媒体原文 ↗